Galecto to Present Poster at Upcoming ATS 2023 International Conference
17 mai 2023 16h01 HE
|
Galecto, Inc.
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
Galecto Reports First Quarter Operating and Financial Results
28 avr. 2023 08h00 HE
|
Galecto, Inc.
BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...
Galecto to Present Two Posters at AACR Annual Meeting 2023
13 avr. 2023 08h30 HE
|
Galecto, Inc.
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
09 mars 2023 07h00 HE
|
Galecto, Inc.
BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
02 mars 2023 16h05 HE
|
Galecto, Inc.
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...
Galecto to Participate in SVB Securities Global Biopharma Conference
01 févr. 2023 08h00 HE
|
Galecto, Inc.
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
07 déc. 2022 16h05 HE
|
Galecto, Inc.
Intermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients GB2064 is...
Galecto Reports Third Quarter Operating and Financial Results
08 nov. 2022 09h15 HE
|
Galecto, Inc.
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
08 nov. 2022 06h00 HE
|
Galecto, Inc.
Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar...
Galecto to Participate in Jefferies London Healthcare Conference
03 nov. 2022 08h00 HE
|
Galecto, Inc.
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...